Source comparison
Head-to-Head vs. Cross-Trial: The Only Fair Comparisons
This is the section that keeps the rest honest. No study has ever administered Melanotan 1 and Melanotan 2 to comparable subjects and measured them against each other. They were developed for different endpoints — medical photoprotection versus cosmetic tannin
This comparison does not assign a generated winner or score.
- This is the section that keeps the rest honest. No study has ever administered Melanotan 1 and Melanotan 2 to comparable subjects and measured them against each other. They were developed for different endpoints — medical photoprotection versus cosmetic tanning and sexual function — so a claim that one “tans better” or is “safer” than the other is stitched together from unrelated studies. Cross-trial inference can frame a hypothesis; it cannot rank the two. The table below grades each available line of evidence by the strength of its underlying design.
- Melanotan 1 (afamelanotide) increases pain-free light exposure in EPP
- Two multicenter randomized, double-blind, placebo-controlled trials[1]
- Well supported for that specific disease and endpoint; the basis of its approval
- Melanotan 1 for broader pigmentary / photodermatologic uses
- Narrative reviews of an orphan drug[3]
- Investigational; not approved for these uses
- Melanotan 2 tans skin safely and effectively
- No efficacy RCT; anecdote only
- Not established; unproven and unlicensed
- Melanotan 2 causes melanocytic-nevus change / melanoma
- Case reports / case series[4][5]
- A genuine safety signal; causality not established, monitoring advised
- Melanotan 1 “beats” Melanotan 2 (or vice versa)
- No head-to-head trial
- Cannot be claimed from evidence; cross-trial only
- Notice the pattern: the only high-tier, well-designed evidence in the entire pair belongs to Melanotan 1 for a rare disease — not to the cosmetic-tanning use that drives most searches, and not to Melanotan 2 at all.